The α3 mutation significantly reduces the binding of MHC tetramer to human CD8. To minimizes the aberrant effect of some CD8 antibodies; clone SFCI21Thy2D3 (also known as “T8”) is recommended.
| Product Specifications | |
| Application | FC |
| Reactivity | Human |
| Conjugation | APC |
| Peptide Sequence | AYACNTSTL |
| Citations for T-Select HLA-A*24:02 survivin-2B Tetramer-AYACNTSTL-APC – 2 Found |
| Kameshima, Hidekazu; Tsuruma, Tetsuhiro; Torigoe, Toshihiko; Takahashi, Akari; Hirohashi, Yoshihiko; Tamura, Yasuaki; Tsukahara, Tomohide; Ichimiya, Shingo; Kanaseki, Takayuki; Iwayama, Yuji; Sato, Noriyuki; Hirata, Koichi. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Science. 2011;102(6):1181-7. PubMed |
| Miyazaki, Akihiro; Kobayashi, Junichi; Torigoe, Toshihiko; Hirohashi, Yoshihiko; Yamamoto, Takashi; Yamaguchi, Akira; Asanuma, Hiroko; Takahashi, Akari; Michifuri, Yoshitaka; Nakamori, Kenji; Nagai, Itaru; Sato, Noriyuki; Hiratsuka, Hiroyoshi. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Science. 2011;102(2):324-9. PubMed |